{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T19:52:14Z","timestamp":1774122734194,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Medical Research Fund of Guangdong Province","award":["A2024662"],"award-info":[{"award-number":["A2024662"]}]},{"name":"Scientific Research Fund Project of Yunnan Provincial Department of Education","award":["2025Y0380"],"award-info":[{"award-number":["2025Y0380"]}]},{"name":"Innovation Fund for Graduate Students of Kunming Medical University","award":["2025S090"],"award-info":[{"award-number":["2025S090"]}]},{"name":"First-Class Discipline Team of Kunming Medical University","award":["2024XKTDYS03"],"award-info":[{"award-number":["2024XKTDYS03"]}]},{"name":"Funding of the National Natural Science Foundation of China","award":["82360603"],"award-info":[{"award-number":["82360603"]}]},{"name":"Yunnan Provincial Science and Technology Department Applied Basic Research-Joint Special Project of Kunming Medical University","award":["202201AY070001-108"],"award-info":[{"award-number":["202201AY070001-108"]}]},{"name":"Basic Research Projects Foundation of the Yunnan Provincial Science, the Technology Department","award":["202201AU070201"],"award-info":[{"award-number":["202201AU070201"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-03033-0","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T02:00:25Z","timestamp":1755050425000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Potential of APOBEC3B as a therapeutic target and its role in bladder cancer onset and progression"],"prefix":"10.1186","volume":"30","author":[{"given":"Zexi","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haihao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haifeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiansong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingxia","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinglong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"3033_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"3033_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076743","volume":"384","author":"A Lopez-Beltran","year":"2024","unstructured":"Lopez-Beltran A, Cookson MS, Guercio BJ, Cheng L. Advances in diagnosis and treatment of bladder cancer. BMJ. 2024;384: e076743.","journal-title":"BMJ"},{"key":"3033_CR3","doi-asserted-by":"publisher","first-page":"5976","DOI":"10.3390\/cancers14235976","volume":"14","author":"Y Gao","year":"2022","unstructured":"Gao Y, Nie Z, Cao H, et al. Scabertopin derived from elephantopus scaber L. mediates necroptosis by inducing reactive oxygen species production in bladder cancer in vitro. Cancers (Basel). 2022;14:5976.","journal-title":"Cancers (Basel)"},{"key":"3033_CR4","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12859-022-04862-0","volume":"23","author":"J Wu","year":"2022","unstructured":"Wu J, Li N, Zhu L, et al. Multiple roles of apolipoprotein B mRNA editing enzyme catalytic subunit 3B (APOBEC3B) in human tumors: a pan-cancer analysis. BMC Bioinform. 2022;23:312.","journal-title":"BMC Bioinform"},{"key":"3033_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13045-023-01425-5","volume":"16","author":"K Butler","year":"2023","unstructured":"Butler K, Banday AR. APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential. J Hematol Oncol. 2023;16:31.","journal-title":"J Hematol Oncol"},{"key":"3033_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.996115","volume":"12","author":"X Yang","year":"2022","unstructured":"Yang X, Dai J, Yao S, et al. APOBEC3B: future direction of liver cancer research. Front Oncol. 2022;12: 996115.","journal-title":"Front Oncol"},{"key":"3033_CR7","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1038\/s41588-023-01504-w","volume":"55","author":"JL McCann","year":"2023","unstructured":"McCann JL, Cristini A, Law EK, et al. APOBEC3B regulates R-loops and promotes transcription-associated mutagenesis in cancer. Nat Genet. 2023;55:1721\u201334.","journal-title":"Nat Genet"},{"key":"3033_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.864889","volume":"12","author":"Z Wei","year":"2022","unstructured":"Wei Z, Gan J, Feng X, et al. APOBEC3B is overexpressed in cervical cancer and promotes the proliferation of cervical cancer cells through apoptosis, cell cycle, and p53 pathway. Front Oncol. 2022;12: 864889.","journal-title":"Front Oncol"},{"key":"3033_CR9","doi-asserted-by":"publisher","first-page":"2147494","DOI":"10.1155\/2022\/2147494","volume":"2022","author":"L He","year":"2022","unstructured":"He L, Yang B, Jian D, Luo H, Wang D, Dai N. Prognostic value of HPV E6 and APOBEC3B in upper urinary tract urothelial carcinoma. Dis Markers. 2022;2022:2147494.","journal-title":"Dis Markers"},{"key":"3033_CR10","doi-asserted-by":"publisher","first-page":"1489324","DOI":"10.3389\/fgene.2024.1489324","volume":"15","author":"J Lehle","year":"2024","unstructured":"Lehle J, Soleimanpour M, Mokhtari S, Ebrahimi D. Viral infection, APOBEC3 dysregulation, and cancer. Front Genet. 2024;15:1489324.","journal-title":"Front Genet"},{"key":"3033_CR11","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1126\/science.1243462","volume":"343","author":"J Lucifora","year":"2014","unstructured":"Lucifora J, Xia Y, Reisinger F, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 2014;343:1221\u20138.","journal-title":"Science"},{"key":"3033_CR12","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.3390\/v14122653","volume":"14","author":"GR de Oliveira","year":"2022","unstructured":"de Oliveira GR, Carvalho PS, Vieira VC, et al. High APOBEC3B mRNA expression is associated with human papillomavirus type 18 infection in cervical cancer. Viruses. 2022;14:2653.","journal-title":"Viruses"},{"key":"3033_CR13","doi-asserted-by":"publisher","first-page":"7222","DOI":"10.1158\/0008-5472.CAN-13-1753","volume":"73","author":"B Leonard","year":"2013","unstructured":"Leonard B, Hart SN, Burns MB, et al. APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Res. 2013;73:7222\u201331.","journal-title":"Cancer Res"},{"key":"3033_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s12032-016-0739-7","volume":"33","author":"K Kosumi","year":"2016","unstructured":"Kosumi K, Baba Y, Ishimoto T, et al. APOBEC3B is an enzymatic source of molecular alterations in esophageal squamous cell carcinoma. Med Oncol. 2016;33:26.","journal-title":"Med Oncol"},{"key":"3033_CR15","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1136\/gutjnl-2018-317601","volume":"68","author":"D Wang","year":"2019","unstructured":"Wang D, Li X, Li J, et al. APOBEC3B interaction with PRC2 modulates microenvironment to promote HCC progression. Gut. 2019;68:1846\u201357.","journal-title":"Gut"},{"key":"3033_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1601737","volume":"2","author":"EK Law","year":"2016","unstructured":"Law EK, Sieuwerts AM, LaPara K, et al. The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer. Sci Adv. 2016;2: e1601737.","journal-title":"Sci Adv"},{"key":"3033_CR17","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/s41467-020-14568-7","volume":"11","author":"CB Driscoll","year":"2020","unstructured":"Driscoll CB, Schuelke MR, Kottke T, et al. APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy. Nat Commun. 2020;11:790.","journal-title":"Nat Commun"},{"key":"3033_CR18","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s12672-014-0196-8","volume":"5","author":"AM Sieuwerts","year":"2014","unstructured":"Sieuwerts AM, Willis S, Burns MB, et al. Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers. Horm Cancer. 2014;5:405\u201313.","journal-title":"Horm Cancer"},{"key":"3033_CR19","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.3390\/ijms23105319","volume":"23","author":"R Kotolloshi","year":"2022","unstructured":"Kotolloshi R, Gajda M, Grimm MO, Steinbach D. Wnt\/\u03b2-catenin signalling and its cofactor BCL9L have an oncogenic effect in bladder cancer cells. Int J Mol Sci. 2022;23:5319.","journal-title":"Int J Mol Sci"},{"key":"3033_CR20","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.3390\/curroncol28030154","volume":"28","author":"H Kim","year":"2021","unstructured":"Kim H, Kim O, Lee MA, et al. Prognostic impact of APOBEC3B expression in metastatic urothelial carcinoma and its association with tumor-infiltrating cytotoxic T cells. Curr Oncol. 2021;28:1652\u201362.","journal-title":"Curr Oncol"},{"issue":"1","key":"3033_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/14796694.2024.2442300","volume":"21","author":"F Yang","year":"2025","unstructured":"Yang F, Xiao H, Dai X, et al. Impact of APOBEC3s on the occurrence, development and prognosis of esophageal squamous cell carcinoma. Future Oncol. 2025;21(1):117\u201325.","journal-title":"Future Oncol"},{"key":"3033_CR22","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu T, Hu E, Xu S, et al. ClusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation (Camb). 2021;2: 100141.","journal-title":"Innovation (Camb)"},{"key":"3033_CR23","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28:1747\u201356.","journal-title":"Genome Res"},{"key":"3033_CR24","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.euf.2024.08.008","volume":"11","author":"M Radi\u0107","year":"2025","unstructured":"Radi\u0107 M, Egger M, Kruithof-de Julio M, Seiler R. Patient-derived organoids in bladder cancer: opportunities and challenges. Eur Urol Focus. 2025;11:62\u201370.","journal-title":"Eur Urol Focus"},{"key":"3033_CR25","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1186\/s12885-022-09783-y","volume":"22","author":"L Jiang","year":"2022","unstructured":"Jiang L, Chen S, Pan Q, et al. The feasibility of proteomics sequencing based immune-related prognostic signature for predicting clinical outcomes of bladder cancer patients. BMC Cancer. 2022;22:676.","journal-title":"BMC Cancer"},{"key":"3033_CR26","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3390\/diagnostics13030569","volume":"13","author":"G Fanourakis","year":"2023","unstructured":"Fanourakis G, Kyrodimos E, Papanikolaou V, et al. APOBEC3B Is co-expressed with PKC\u03b1\/NF-\u03baB in oral and oropharyngeal squamous cell carcinomas. Diagnostics (Basel). 2023;13:569.","journal-title":"Diagnostics (Basel)"},{"key":"3033_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.888250","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Wu Z, Hao Y, et al. Aberrantly activated APOBEC3B is associated with mutant p53-driven refractory\/relapsed diffuse large B-cell lymphoma. Front Immunol. 2022;13: 888250.","journal-title":"Front Immunol"},{"key":"3033_CR28","volume":"60","author":"GF Ho","year":"2025","unstructured":"Ho GF, Lee SC, Bustam AZ, et al. Pembrolizumab monotherapy for previously treated metastatic HER2-negative breast cancer with germline APOBEC3B deletion: results of the phase II AUROR study. Lancet Reg Health. 2025;60: 101637.","journal-title":"Lancet Reg Health"},{"key":"3033_CR29","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41586-022-04972-y","volume":"607","author":"M Petljak","year":"2022","unstructured":"Petljak M, Dananberg A, Chu K, et al. Mechanisms of APOBEC3 mutagenesis in human cancer cells. Nature. 2022;607:799\u2013807.","journal-title":"Nature"},{"key":"3033_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.xgen.2024.100528","volume":"4","author":"JA Nakauma-Gonz\u00e1lez","year":"2024","unstructured":"Nakauma-Gonz\u00e1lez JA, Rijnders M, Noordsij MTW, et al. Whole-genome mapping of APOBEC mutagenesis in metastatic urothelial carcinoma identifies driver hotspot mutations and a novel mutational signature. Cell Genom. 2024;4: 100528.","journal-title":"Cell Genom"},{"key":"3033_CR31","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/mc.23292","volume":"60","author":"Q Fan","year":"2021","unstructured":"Fan Q, Huang T, Sun X, et al. HPV-16\/18 E6-induced APOBEC3B expression associates with proliferation of cervical cancer cells and hypomethylation of cyclin D1. Mol Carcinog. 2021;60:313\u201330.","journal-title":"Mol Carcinog"},{"key":"3033_CR32","doi-asserted-by":"publisher","first-page":"1537808","DOI":"10.3389\/fimmu.2025.1537808","volume":"16","author":"P Huang","year":"2025","unstructured":"Huang P, Wang J, Yu Z, Lu J, Sun Z, Chen Z. Redefining bladder cancer treatment: innovations in overcoming drug resistance and immune evasion. Front Immunol. 2025;16:1537808.","journal-title":"Front Immunol"},{"key":"3033_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/cimb47040278","volume":"47","author":"HJ Oyler","year":"2025","unstructured":"Oyler HJ, Bruton LG, Maher AJ, et al. Cytokine therapy in bladder cancer: mechanisms, efficacy, and future prospects. Curr Issues Mol Biol. 2025;47: 278.","journal-title":"Curr Issues Mol Biol"},{"key":"3033_CR34","doi-asserted-by":"publisher","first-page":"4725","DOI":"10.1073\/pnas.1424795112","volume":"112","author":"MT Cheah","year":"2015","unstructured":"Cheah MT, Chen JY, Sahoo D, et al. CD14-expressing cancer cells establish the inflammatory and proliferative tumor microenvironment in bladder cancer. Proc Natl Acad Sci U S A. 2015;112:4725\u201330.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3033_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2024.101103","volume":"60","author":"R Nakagawa","year":"2025","unstructured":"Nakagawa R, Izumi K, Hiratsuka K, et al. Tumor-associated macrophages promote bladder cancer metastasis through the CCL20-CCR6 axis. Neoplasia. 2025;60: 101103.","journal-title":"Neoplasia"},{"key":"3033_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003416","volume":"10","author":"Y Xu","year":"2022","unstructured":"Xu Y, Zeng H, Jin K, et al. Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer. J Immunother Cancer. 2022;10: e003416.","journal-title":"J Immunother Cancer"},{"key":"3033_CR37","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1172\/JCI90387","volume":"127","author":"JA Wagner","year":"2017","unstructured":"Wagner JA, Rosario M, Romee R, et al. CD56bright NK cells exhibit potent antitumor responses following IL-15 priming. J Clin Invest. 2017;127:4042\u201358.","journal-title":"J Clin Invest"},{"key":"3033_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.919274","volume":"9","author":"Q Zhao","year":"2022","unstructured":"Zhao Q, Hu W, Xu J, et al. Comprehensive pan-cancer analysis of senescence with cancer prognosis and immunotherapy. Front Mol Biosci. 2022;9: 919274.","journal-title":"Front Mol Biosci"},{"key":"3033_CR39","volume":"32","author":"Z Cheng","year":"2022","unstructured":"Cheng Z, Han J, Jiang F, Chen W, Ma X. Prognostic pyroptosis-related lncRNA signature predicts the efficacy of immunotherapy in hepatocellular carcinoma. Biochem Biophys Rep. 2022;32: 101389.","journal-title":"Biochem Biophys Rep"},{"key":"3033_CR40","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","volume":"39","author":"DL Jardim","year":"2021","unstructured":"Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 2021;39:154\u201373.","journal-title":"Cancer Cell"},{"key":"3033_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002309","volume":"14","author":"A Snyder","year":"2017","unstructured":"Snyder A, Nathanson T, Funt SA, et al. Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: an exploratory multi-omic analysis. PLoS Med. 2017;14: e1002309.","journal-title":"PLoS Med"},{"key":"3033_CR42","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389:67\u201376.","journal-title":"Lancet"},{"key":"3033_CR43","doi-asserted-by":"publisher","first-page":"1975386","DOI":"10.1080\/2162402X.2021.1975386","volume":"10","author":"S Xia","year":"2021","unstructured":"Xia S, Gu Y, Zhang H, et al. Immune inactivation by APOBEC3B enrichment predicts response to chemotherapy and survival in gastric cancer. Oncoimmunology. 2021;10:1975386.","journal-title":"Oncoimmunology"},{"key":"3033_CR44","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1038\/s41388-018-0245-9","volume":"37","author":"S Wang","year":"2018","unstructured":"Wang S, Jia M, He Z, Liu XS. APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer. Oncogene. 2018;37:3924\u201336.","journal-title":"Oncogene"},{"key":"3033_CR45","doi-asserted-by":"publisher","first-page":"6042334","DOI":"10.1155\/2022\/6042334","volume":"2022","author":"C Zhang","year":"2022","unstructured":"Zhang C, Cheng Z, Wang Z, Zhao G, Yuan Y, Wang R. APOBEC3B and CD274 as combined biomarkers for predicting response to immunotherapy in urothelial carcinoma of the bladder. J Oncol. 2022;2022:6042334.","journal-title":"J Oncol"},{"key":"3033_CR46","doi-asserted-by":"publisher","first-page":"27702","DOI":"10.1038\/srep27702","volume":"6","author":"SA Mullane","year":"2016","unstructured":"Mullane SA, Werner L, Rosenberg J, et al. Correlation of apobec mrna expression with overall survival and pd-l1 expression in urothelial carcinoma. Sci Rep. 2016;6:27702.","journal-title":"Sci Rep"},{"key":"3033_CR47","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/MOU.0000000000001263","volume":"35","author":"S Ruder","year":"2025","unstructured":"Ruder S, Martinez J, Palmer J, Arham AB, Tagawa ST. Antibody-drug conjugates in urothelial carcinoma: current status and future. Curr Opin Urol. 2025;35:292\u2013300.","journal-title":"Curr Opin Urol"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03033-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-03033-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03033-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T01:43:16Z","timestamp":1757382196000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-03033-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3033"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-03033-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6204060\/v1","asserted-by":"object"}]},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"assertion":[{"value":"11 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This investigation was approved by the Human Ethics Committee of The Second Hospital of Kunming Medical University that provided human bladder samples. The approval number of the human experiments: SHEN-PJ-KE-2023\u201301. The written informed consent was obtained from all study participants. All animal procedures were approved by the Medical Ethics Committee of Kunming Medical University (kmmu20211129).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"740"}}